about
H5N1 vaccines in humansFluad®-MF59®-Adjuvanted Influenza Vaccine in Older AdultsThe Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in MiceUse of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoproteinEmulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in miceAn update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adultsA dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for childrenIdentification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Emulsion-based adjuvants for influenza vaccines.In Vivo Analysis of the Potency of Silicone Oil Microdroplets as Immunological Adjuvants in Protein FormulationsMF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxisMF59™ as a vaccine adjuvant: a review of safety and immunogenicity.Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.Inactivated influenza vaccines: recent progress and implications for the elderly.MF59 adjuvant: the best insurance against influenza strain diversity.Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.Aflunov(®): a prepandemic influenza vaccine.Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.Novel viral vectored vaccines for the prevention of influenza.Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza.Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvantMultiparameter telemetry as a sensitive screening method to detect vaccine reactogenicity in miceGlycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.Vaccine Potentiation by Combination AdjuvantsImmunosenescence and Challenges of Vaccination against Influenza in the Aging Population.Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccinesDevelopmental biology of the innate immune response: implications for neonatal and infant vaccine development.Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.The ABC of clinical and experimental adjuvants--a brief overview.MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.Combination adjuvants: the next generation of adjuvants?Use of defined TLR ligands as adjuvants within human vaccines.Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement.Immunomodulatory properties of vitamins, flavonoids and plant oils and their potential as vaccine adjuvants and delivery systems.Improving immunogenicity and effectiveness of influenza vaccine in older adults.
P2860
Q27000896-0AC75B21-C91F-4D22-8C26-0B9ABF69A775Q27009478-3496F532-91E2-4A93-BDD0-BC12DF1F29C3Q28552440-AC81197D-6134-4F83-9C65-C12FB852F1C0Q28730561-EB5A13B0-CE03-4862-9283-8B8EB5B2FE27Q28749625-6A504963-690C-4B96-B88E-48E586BDC04EQ30352329-9205FCF3-FCA4-4B1D-BCDF-B2FC045FCCF6Q30353708-A7A64E0D-9565-410B-AC02-5B6FAFAD8184Q30368934-DFBCCD5F-2054-4144-9E44-DD7C7EFF3F1FQ30371111-C1B06147-F374-4B79-9130-8F0537648A89Q30371303-C919C361-8F33-40AD-9A63-953B0800092BQ30375985-2BCD88C8-91F5-4DE1-8BB9-CDAE47AF0A12Q30376902-B520C830-E66B-4DB3-8119-D0E7FDF4F871Q30377215-4AC4D801-27D3-4EA3-88AE-4A0018B46A84Q30394545-017D8886-3F3E-47E1-9CBE-5578ED90B4A6Q30396654-8E28A872-9645-46AA-91DA-BFA56A2DAFBEQ30399057-D00A887E-D844-42EC-A7FD-DD20D654092FQ30402018-E51A1495-7538-4E2A-B7F4-6FB20FD9F83DQ30406937-D92FA303-346E-4609-AD3D-AB1B45B3F9D7Q30412222-69E20D63-4C0B-4DA2-B73E-90D75426E7E8Q30412628-C136C1A2-CC70-4122-83E8-D7F3B2B7FA56Q30413695-F1128A25-9EC5-4905-B991-5F5BE8863976Q30418570-FE1A6C31-3508-4241-8C00-010AD0362139Q30424161-2B13D108-FF8A-4390-A1C8-3BDD8A1AF3F5Q33503623-A5A44A6F-959E-425D-BF8C-EB2596152FA5Q33585524-8CF5FCAE-8518-4BD7-8890-ACA09E63FEC7Q34140252-D7643100-460C-4D46-9336-489D7F668144Q34988279-A5DCC247-EDC8-4465-B063-E4F4798CC324Q35826767-96EFE03B-7D22-42FD-8686-F2D48A008504Q35874111-BC98A6A7-7D7B-435C-89D6-676CE7CA7CBDQ35887626-6E0B4855-54D4-4D9E-A36A-89E8122FB2DFQ37478319-33E34D3B-5D47-4275-9DD8-D491477C7ECFQ37482390-88395578-F1F4-4F21-8066-847A028C4965Q37523971-8B006599-A27C-4FB7-98C0-F9B154B11465Q37628867-666C5519-8334-47E8-8264-922FCD239812Q37706610-A56EC98B-ECAE-4585-BC12-67D787A68032Q37821483-9359B6BA-E825-46E7-B8D5-55C8ED3B9929Q37825528-F127B3E0-AC49-4264-9DBF-1E2D277B4137Q37836900-7223BD87-0699-43FA-9D64-DEB8718212E0Q37939970-F230BDCE-32EF-4ABC-AFDE-584E723CD57EQ37951523-73E8E44A-C569-4E8C-A738-BC19605441CF
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety of MF59 adjuvant.
@en
Safety of MF59 adjuvant.
@nl
type
label
Safety of MF59 adjuvant.
@en
Safety of MF59 adjuvant.
@nl
prefLabel
Safety of MF59 adjuvant.
@en
Safety of MF59 adjuvant.
@nl
P2093
P1433
P1476
Safety of MF59 adjuvant.
@en
P2093
Deborah Novicki
Juergen Zorn
Renald Hennig
Vicente D'Agosto
Viola Schultze
P304
P356
10.1016/J.VACCINE.2008.03.093
P407
P50
P577
2008-04-21T00:00:00Z